Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I-Reference-Cited by-同舟云学术

Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I

Published:2022-02-01 Issue:1 Volume:41 Page:4-22
ISSN:0730-031X
Container-title:Biotechnology Law Report
language:en
Short-container-title:Biotechnology Law Report

Author:

Holman Christopher M.¹

Affiliation:

1. Christopher M. Holman is a Professor of Law at the University of Missouri–Kansas City School of Law; a Senior Fellow at the Center for Intellectual Property x Innovation Policy (CIP-2) at the Antonin Scalia Law School, George Mason University; and the Executive Editor of Biotechnology Law Report.

Publisher

Mary Ann Liebert Inc

Subject

Management, Monitoring, Policy and Law,Biotechnology

Link

https://www.liebertpub.com/doi/pdf/10.1089/blr.2022.29259.cmh

Reference8 articles.

1. In Juno v. Kite the Federal Circuit Strikes Down Patent Directed Towards Pioneering Innovation in CAR T-Cell Therapy

2. In Defense of Secondary Pharmaceutical Patents: A Response to the UN's Guidelines for Pharmaceutical Patent Examination

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. When mRNA technology meets patent law: innovation, barriers and public health;Journal Of Intellectual Property Law and Practice;2023-10-31

2. When mRNA Technology Meets Patent Law: Innovation, Barriers, and the Public Health;SSRN Electronic Journal;2023

3. The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words);Biotechnology Law Report;2022-10-01

4. The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR;Biotechnology Law Report;2022-06-01

5. Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II;Biotechnology Law Report;2022-04-01